April 7, 2023

BOLD Innovation That Matters: Episode 2

Date and time

April 27, 2023 ~ April 27, 2023

8AM – 10AM PDT and 8PM – 10PM PDT

Dear Colleagues & Friends,

We are pleased to announce the success of the BOLD Innovation That Matters: Episode 2 virtual event. The event brought together over 30 leading experts from the life science ecosystem who shared innovative solutions to some of the most complex scientific challenges facing the industry today.

During the event, experts engaged in thought-provoking discussions on a range of topics, including State of BOLD Innovation 2023, Druggability Redefined, RNA Therapeutics, and the Next Generation of Cell and Gene Therapies. The discussions were led by session leaders and CEOs of prominent companies in the industry.

We would like to extend our sincere thanks to all the guest speakers for sharing their valuable insights and knowledge with us. We would also like to thank our viewers for their participation, which helped make the event a resounding success.

At BOLD Innovation That Matters, we remain committed to fostering innovation and working together to address global health challenges. We look forward to bringing together more experts in the future to continue these important discussions.

Thank you to everyone who made this event a success.

Agenda

08:00 AM - 08:05 AM Welcome
Hui Cai, Program Chair and Vice President, WuXi AppTec
08:05 AM - 08:45 AM Opening Plenary: State of BOLD Innovation 2023
Sabine Dandiguian, Managing Partner, Jeito Capital
Matthew Ellis, SVP, Early Oncology R&D, AstraZeneca
David Schenkein, General Partner, GV
James Wilson, Professor of Medicine and Pediatrics of Department of Medicine, and Director of Gene Therapy Program, University of Pennsylvania
Session Leader: Edward Hu, Vice Chairman, WuXi AppTec
08:45 AM - 09:10 AM Breaking Barriers: Druggability Redefined
Laksh Aithani, CEO & Co-Founder, CHARM Therapeutics
Marcelo Bigal, President & CEO, Ventus Therapeutics
Ping Cao, Co-Founder & CEO, BridGene Biosciences
Michael Gilman, CEO, Arrakis Therapeutics
SJ Lee, CEO, Orum Therapeutics
Eddine Saiah, CSO, Stablix
Dennis Zaller, CSO, ROME Therapeutics
Lily Zou, Co-Founder & CEO, Degron Therapeutics
09:10 AM - 09:35 AM Opening New Horizons: Spotlight on RNA Therapeutics
Josh Mandel-Brehm, President & CEO, CAMP4 Therapeutics
Jack O'Meara, CEO, Ochre Bio
Carsten Rudolph, CEO & Founder, Ethris
Stella Shi, Founder & CEO, Rona Therapeutics
Arthur Suckow, CEO, DTx Pharma
Shehnaaz Suliman, CEO, ReCode Therapeutics
Jan Thirkettle, CEO, Transine Therapeutics
09:35 AM - 10:00 AM Leading Next Generation of Cell and Gene Therapies
Jeff Bluestone, CEO & Co-Founder, Sonoma Biotherapeutics; Professor Emeritus, UCSF Diabetes Center
Theresa Heah, CEO, Intergalactic Therapeutics
Reagan Jarvis, CEO & Co-Founder, Anocca
Phil Johnson, President & CEO, Interius BioTherapeutics
Paul Lammers, CEO, Triumvira Immunologics
Peter Maag, CEO, Kyverna Therapeutics
Devyn Smith, CEO, Arbor Biotechnologies
Thomas Willemsen, President & CEO, Tessa Therapeutics
Caroline Xu, Co-Founder & CEO, ViGeneron
10:00 AM - 10:05 AM Closing Remarks
Richard Soll, Head of Boston Office and Senior Advisor of Strategic Initiatives, WuXi AppTec

Speakers

Hui Cai
Program Chair and Vice President, WuXi AppTec
Sabine Dandiguian
Managing Partner, Jeito Capital
Matthew Ellis
SVP, Early Oncology R&D, AstraZeneca
David Schenkein
General Partner, GV
James Wilson
Professor of Medicine and Pediatrics of Department of Medicine, and Director of Gene Therapy Program, University of Pennsylvania
Edward Hu
Vice Chairman, WuXi AppTec
Laksh Aithani
CEO & Co-Founder, CHARM Therapeutics
Marcelo Bigal
President & CEO, Ventus Therapeutics
Ping Cao
Co-Founder & CEO, BridGene Biosciences
Michael Gilman
CEO, Arrakis Therapeutics
SJ Lee
CEO, Orum Therapeutics
Eddine Saiah
CSO, Stablix
Dennis Zaller
CSO, ROME Therapeutics
Lily Zou
Co-Founder & CEO, Degron Therapeutics
Josh Mandel-Brehm
President & CEO, CAMP4 Therapeutics
Jack O'Meara
CEO, Ochre Bio
Carsten Rudolph
CEO & Founder, Ethris
Stella Shi
Founder & CEO, Rona Therapeutics
Arthur Suckow
CEO, DTx Pharma
Shehnaaz Suliman
CEO, ReCode Therapeutics
Jan Thirkettle
CEO, Transine Therapeutics
Jeff Bluestone
CEO & Co-Founder, Sonoma Biotherapeutics; Professor Emeritus, UCSF Diabetes Center
Theresa Heah
CEO, Intergalactic Therapeutics
Reagan Jarvis
CEO & Co-Founder, Anocca
Phil Johnson
President & CEO, Interius BioTherapeutics
Paul Lammers
CEO, Triumvira Immunologics
Peter Maag
CEO, Kyverna Therapeutics
Devyn Smith
CEO, Arbor Biotechnologies
Thomas Willemsen
President & CEO, Tessa Therapeutics
Caroline Xu
Co-Founder & CEO, ViGeneron
Richard Soll
Head of Boston Office and Senior Advisor of Strategic Initiatives, WuXi AppTec